Tropism Results and Resistance Testing in Adolescent Master Protocol, PH200

Tropism Results and Resistance Testing (July 2024). Data updated in 2024 in DASH to include the follow-up time points through the final participant visit in 2020.
Study Description
The PHACS AMP study is designed to define the impact of HIV infection and antiretroviral therapy on pre-adolescents and adolescents with perinatal HIV infection. Domains investigated include growth and sexual maturation; metabolic risk factors for cardiovascular disease; cardiac function; bone health; neurologic, neurodevelopment, language, hearing, and behavioral function; and adolescent gynecology and HPV infection. Biospecimens are available. AMP includes 451 perinatally HIV-infected (PHIV) youth and 227 perinatally HIV-exposed uninfected (PHEU) youth, age 6 to 17 years at study entry. [587 caregivers also enrolled to provide information on their children.]

病毒嗜性结果与耐药性检测（2024年7月）。本数据集于2024年通过DASH系统完成更新，纳入了截至2020年受试者末次随访的全部随访时间点数据。
研究概况
PHACS AMP研究旨在明确HIV感染与抗反转录病毒治疗对围产期HIV感染青春前期及青少年人群的影响。本研究所覆盖的研究领域包括生长发育与性成熟、心血管疾病代谢危险因素、心脏功能、骨骼健康、神经功能、神经发育、语言能力、听力水平与行为功能，以及青少年妇科与人乳头瘤病毒（Human Papillomavirus, HPV）感染。本研究可提供生物标本。该研究共纳入451名围产期HIV感染（perinatally HIV-infected, PHIV）青少年，以及227名围产期HIV暴露但未感染（perinatally HIV-exposed uninfected, PHEU）青少年，入组时年龄为6至17岁。另有587名照护者入组，以提供其子女的相关研究信息。